Hepatitis C medications have been making news lately, as the newest drugs have topped insurance companies’ lists of costliest drugs – and only after being on the Canadian market for 6 months. At approximately $1200/pill, it’s not hard to see why.
Drug payors have been looking for ways to manage the looming cost of these medications, like Harvoni, while keeping their employees safe and healthy.
A new white paper by Personalized Prescribing Inc. describes the past and current landscape of Hepatitis C treatment, and proposes a way to manage the high cost of Harvoni that are beginning to make a significant impact on drug plans across the country.
To read the white paper, click the link below.